Muscle Nutrition: Evidence Review for Protein, Leucine, and HMB Products | Market Intelligence

Description

List of Tables

Between sarcopenia diagnosis and sarcopenia pharmacotherapy sits a large commercial middle ground: nutritional products that claim to preserve or rebuild muscle. In Japan this ground is unusually crowded. Ajinomoto markets a leucine-enriched amino-acid blend supported by domestic trial data, Abbott sells HMB-containing medical nutrition, dairy and ingredient companies from Meiji to Arla supply protein fractions into senior-product lines, and hundreds of muscle-function claims sit inside Japan's Foods with Function Claims notification system. For R&D and business development teams, the question is no longer whether the category exists but which products rest on evidence that survives scrutiny.

That scrutiny has become harder to fake. The FFC framework now applies PRISMA-based systematic-review requirements to health claims, and the global literature on protein, leucine, and HMB has matured into a mix of well-powered trials, underpowered studies, and meta-analyses that point in different directions depending on population and endpoint. Companies face a dual burden: building claims that regulators will accept and building formulations whose evidence will convince clinicians, dietitians, and institutional buyers. Ingredient suppliers, in turn, must decide which fractions and doses to back with proprietary trials.

This report is an evidence-versus-claim review built for commercial use. It assembles the clinical literature on protein, leucine, HMB, and combination formulations in older and sarcopenic populations; maps the marketed product landscape in Japan, the US, EU5, and China against that literature; and examines the regulatory frameworks, FFC and FOSHU in Japan, EFSA claims in Europe, structure-function rules in the US, and blue-hat registration in China, that determine what can be said on a label. Company chapters profile Ajinomoto, Abbott, Meiji, Kyowa Hakko Bio, Nestle Health Science, Danone, DSM-Firmenich, Arla Foods Ingredients, Morinaga Milk, FANCL, Glanbia, FrieslandCampina, and TSI Group, covering product lines, ingredient positions, and evidence strategies.

The report serves food and supplement R&D teams benchmarking formulations, business development teams evaluating ingredient and brand partnerships, ingredient suppliers planning trial investment, and investors assessing the senior-nutrition segment. The evidence grading is structured so readers can trace every claim classification back to its underlying studies.

Scope and Coverage

The report covers protein, leucine, HMB, and related amino-acid products for muscle health across the US, EU5, Japan, and China, spanning medical nutrition, dairy, and supplement channels. Regulatory coverage includes Japan's FFC and FOSHU systems, EFSA health-claim rules, US structure-function regulation, and China's blue-hat system. Pharmaceutical muscle therapies are outside scope.

Report Highlights

Systematic evidence grading for protein, leucine, and HMB interventions in older adults
Product-by-product claim mapping against the supporting literature
FFC and FOSHU regulatory mechanics and the PRISMA-based review requirements
Profiles of brand owners and ingredient suppliers across four regions
Channel analysis: medical nutrition, dairy, pharmacy, and direct-to-consumer
Identification of evidence gaps that represent trial-investment opportunities

Product Code: JPH-004

Table of Content

1. Executive Summary

2. Muscle Nutrition: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

Ajinomoto (JP) - Amino L40 leucine-enriched amino-acid blend with Japanese sarcopenia trial data
Abbott (US) - Abound (HMB) and Ensure protein lines supported by PROVIDE-type muscle trials
Meiji (JP) - whey-protein and fortified dairy products for senior nutrition
Kyowa Hakko Bio (JP) - HMB and amino-acid ingredient research base in Japan
Nestle Health Science (CH) - Resource protein supplements in the medical-nutrition channel
Danone (FR) - Fortimel/Nutricia medical nutrition including HMB-containing products
DSM-Firmenich (CH) - HMB and amino-acid ingredient supply to formulators
Arla Foods Ingredients (DK) - whey-protein and leucine-rich fractions for senior products
Morinaga Milk (JP) - protein-fortified dairy and clinical-nutrition lines
FANCL (JP) - FFC-notified supplements with muscle-function claims
Glanbia (IE) - whey-protein ingredient supplier to Japanese formulators
FrieslandCampina (NL) - dairy-protein ingredients for medical nutrition
TSI Group (CN) - HMB raw-material supply into Asian supplement brands

Product Code: JPH-004

List of Tables

Table 1. Muscle-protein metabolism framework: synthesis, breakdown, and anabolic resistance in aging
Table 2. Intervention taxonomy: protein sources, leucine enrichment, HMB, and combination formulations
Table 3. Evidence-grading framework used in this report: study design, population, and endpoint criteria
Table 4. Regulatory milestones for nutrition health claims in Japan by year
Table 5. Older-adult nutrition populations by setting: community, hospital, and care facility
Table 6. Dietary-protein intake patterns in elderly populations: US, EU5, Japan, and China
Table 7. Malnutrition screening instruments used alongside muscle-nutrition interventions
Table 8. Sarcopenia and frailty cohorts used as target populations in nutrition trials
Table 9. Institutional-purchaser landscape: hospitals, care homes, and home-care programs
Table 10. Current practice landscape: dietary counseling and supplementation in Japanese elder care
Table 11. Protein-intake recommendations across geriatric and sports-nutrition guidelines
Table 12. Medical-nutrition prescribing and dispensing channels in Japan
Table 13. Enteral and oral nutritional supplement product categories
Table 14. Pharmacy, drugstore, and direct-to-consumer supplement channels
Table 15. Ajinomoto Amino L40: leucine-enriched blend composition and Japanese trial program
Table 16. Abbott Abound and Ensure: HMB and protein product lines and the PROVIDE study design
Table 17. Meiji whey-protein and fortified dairy products for senior nutrition
Table 18. Kyowa Hakko Bio HMB and amino-acid ingredient research base
Table 19. Nestle Health Science Resource line in the medical-nutrition channel
Table 20. Danone Nutricia Fortimel products including HMB-containing formulations
Table 21. DSM-Firmenich and Arla Foods Ingredients: HMB, whey, and leucine ingredient supply
Table 22. Morinaga Milk protein-fortified dairy and clinical-nutrition lines
Table 23. FANCL FFC-notified supplements with muscle-function claims
Table 24. Glanbia, FrieslandCampina, and TSI Group: ingredient positions in Asian senior nutrition
Table 25. Protein-intervention evidence base: trial designs and endpoint structures under review
Table 26. Leucine-enrichment evidence base: trial designs and dose frameworks under review
Table 27. HMB evidence base: trial designs and population coverage under review
Table 28. Combination-formulation and exercise co-intervention trial designs
Table 29. Japan FFC notification mechanics for muscle-function claims
Table 30. FOSHU approval pathway and its muscle-health precedents
Table 31. PRISMA 2020 systematic-review requirements applied to FFC claims
Table 32. EFSA health-claim regulation relevant to protein and muscle claims
Table 33. US structure-function claim rules and their enforcement posture
Table 34. China blue-hat registration pathway for muscle-health products
Table 35. Claim-language comparison across the four regulatory systems
Table 36. Pricing and margin structures across medical-nutrition and supplement channels
Table 37. Company positioning map: brand owners versus ingredient suppliers
Table 38. Ajinomoto: amino-acid franchise structure and senior-nutrition strategy
Table 39. Abbott and Nestle Health Science: medical-nutrition channel competition
Table 40. Japanese dairy and supplement players: Meiji, Morinaga, and FANCL positioning
Table 41. Ingredient-supplier strategies: DSM-Firmenich, Arla, Glanbia, FrieslandCampina, and TSI
Table 42. Partnership and licensing structures between ingredient suppliers and brand owners
Table 43. Unmet needs: evidence gaps in muscle-nutrition claims
Table 44. Trial-investment opportunities: populations and endpoints lacking adequate studies
Table 45. Claim-differentiation strategies under the revised FFC evidence rules
Table 46. Japan channel-entry options for foreign ingredient and brand companies
Table 47. Senior-nutrition segment map: adjacent categories and convergence points
Table 48. Monitoring and compliance risk framework for notified claims
Table 49. Report methodology: literature-search protocol, grading rules, and product-audit approach
Table 50. Glossary of ingredients, claims, and regulatory acronyms

List of Figures

Figure 1. Muscle-protein metabolism schematic: synthesis, breakdown, and anabolic resistance
Figure 2. Intervention taxonomy map: protein, leucine, HMB, and combinations
Figure 3. Evidence-grading flow used in this report
Figure 4. Timeline of nutrition health-claim regulation in Japan
Figure 5. Older-adult nutrition population map by care setting
Figure 6. Dietary-protein intake framework across the four regions
Figure 7. Malnutrition screening pathway schematic
Figure 8. Target-population map for muscle-nutrition trials
Figure 9. Institutional-purchaser structure diagram
Figure 10. Current practice flow: counseling and supplementation in Japanese elder care
Figure 11. Protein-recommendation landscape across guidelines
Figure 12. Medical-nutrition prescribing channel map in Japan
Figure 13. Enteral and oral supplement category structure
Figure 14. Pharmacy and direct-to-consumer channel map
Figure 15. Amino L40 composition and trial-program structure
Figure 16. Abound and Ensure product-line architecture and PROVIDE design schematic
Figure 17. Meiji senior-nutrition product map
Figure 18. Kyowa Hakko Bio ingredient research structure
Figure 19. Resource product-line positioning in the medical channel
Figure 20. Fortimel product architecture including HMB formulations
Figure 21. DSM-Firmenich and Arla ingredient-supply structure
Figure 22. Morinaga Milk clinical-nutrition product map
Figure 23. FANCL FFC-notified muscle-claim portfolio structure
Figure 24. Glanbia, FrieslandCampina, and TSI ingredient positions
Figure 25. Protein-trial evidence-map structure: designs and endpoints
Figure 26. Leucine-trial evidence-map structure: designs and doses
Figure 27. HMB-trial evidence-map structure: designs and populations
Figure 28. Combination and exercise co-intervention design schematic
Figure 29. FFC notification flow for muscle-function claims
Figure 30. FOSHU approval pathway flow
Figure 31. PRISMA 2020 review workflow applied to FFC dossiers
Figure 32. EFSA claim-assessment pathway for protein and muscle claims
Figure 33. US structure-function claim framework diagram
Figure 34. China blue-hat registration flow
Figure 35. Claim-language comparison matrix across regulatory systems
Figure 36. Channel pricing and margin structure map
Figure 37. Company positioning map: brand owners versus ingredient suppliers
Figure 38. Ajinomoto amino-acid franchise structure
Figure 39. Medical-nutrition channel competition: Abbott and Nestle Health Science
Figure 40. Japanese dairy and supplement player positioning
Figure 41. Ingredient-supplier strategy map
Figure 42. Ingredient-to-brand partnership network
Figure 43. Evidence-gap map for muscle-nutrition claims
Figure 44. Trial-investment opportunity matrix: populations and endpoints
Figure 45. Claim-differentiation decision tree under revised FFC rules
Figure 46. Japan channel-entry route map for foreign companies
Figure 47. Senior-nutrition segment convergence map
Figure 48. Claim compliance and monitoring risk framework
Figure 49. Methodology flow: literature search, grading, and product audit
Figure 50. Data cut-off and update cadence schematic

Muscle Nutrition: Evidence Review for Protein, Leucine, and HMB Products | Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Muscle Nutrition: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures